To explore the effect of Hushen Jiangtang paste in non dialysis diabetes nephropathy patients with spleen kidney yang deficiency.

Totally 93 patients with non dialysis diabetes nephropathy were selected from the department of nephrology and rheumatology and the department of diabetes in Zhengzhou Hospital of Traditional Chinese Medicine from April 2023 to January 2025. They were divided into the granule group (n = 46) and the paste group (n=47) by lot drawing. During the research process, a total of 3 cases withdrew or were lost to follow-up. Among them, one case in the particle group withdrew due to unwillingness to continue cooperating with treatment; One case was lost to follow-up in the paste group, and one case automatically withdrew. Finally, there were 45 cases in the granule group and 45 cases in the paste group. The granule group was given Urinary Detoxification Granules (sugar free type) orally, while the ointment group was given Hushen Jiangtang paste orally. Compare the clinical efficacy, TCM syndrome score, glucose and lipid metabolism, proteinuria, renal function, meridian characteristics, and adverse reactions between two groups.

The total clinical effective rate of the ointment group was 91.11% (41/45), which was higher than that of the granule group 75.56% (34/45) (P < 0.05). After 24 weeks of treatment, the two groups showed a decrease in overall swelling, pale complexion, cold limbs, cold and painful waist and spine, and mental fatigue scores compared to before treatment(P < 0.05). The plaster group was lower than the granule group (P < 0.05). After 24 weeks of treatment, the levels of TC, TG, LDL-C, FBG, and HbA1c in both groups decreased compared to before treatment(P < 0.05), and the paste group was lower than the granule group (P <0.05). There was no significant difference in Scr levels between the particle group before treatment and 24 weeks after treatment (P > 0.05) ; The Scr level in the ointment group decreased after 24 weeks of treatment compared to before treatment (P < 0.05) ; After 24 weeks of treatment, the Scr level in the ointment group was lower than that in the granule group (P < 0.05) ; After 24 weeks of treatment, the levels of mAlb, 24-hour urine protein quantification(24h UTP), and BUN in both groups decreased compared to before treatment(P < 0.05), and the paste group was lower than the granule group (P <0.05). After 24 weeks of treatment, the physical fitness and Yin/Yang meridian energy index levels of the two groups increased compared to before treatment(P < 0.05), with the ointment group higher than the granule group (P < 0.05); The energy index levels of the upper/lower, autonomic nervous system (P < 0.05), and left/right meridians decreased compared to before treatment(P < 0.05), and the ointment group was lower than the granule group (P < 0.05). According to Fisher's exact probability test, there was no significant difference in the incidence of adverse reactions between the paste group (2.22%, 1/45) and the granule group (6.67%, 3/45) (P >0.05).

Hushen Jiangtang paste can regulate glucose and lipid metabolism, proteinuria, and renal function in non dialysis diabetes nephropathy patients with spleen and kidney yang deficiency, improve the characteristics of meridians, regulate TCM syndrome scores, and has good safety and improve clinical efficacy.

To explore the clinical efficacy of Tongxuan Qishen formula (clearing Xuan and activating kidney Therapy) in treating diabetic nephropathy (DN) patients with spleen and kidney deficiency, blood stasis and water stagnation syndrome.

A total of 85 patients with diabetic nephropathy who met the criteria of spleen and kidney deficiency, blood stasis and water stagnation syndrome, admitted to Wangjing Hospital of China Academy of Chinese Medical Sciences from January 2022 to April 2024, were randomly divided into a control group (receiving basic treatment) and an treatment group (receiving basic treatment + clearing Xuan and activating kidney Therapy). The treatment group consisted of 43 patients, and the control group had 42 patients. The clinical symptoms, FIB-4 index, glucose and lipid metabolism-related indicators [glycated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C)], renal function indicators [24-hour urine total protein (24h UTP), estimated glomerular filtration rate (eGFR), serum creatinine (Scr), blood urea nitrogen (BUN), and uric acid (UA)], and safety indicators were observed and compared between the two groups before and after treatment.

After 12 weeks of intervention, the clinical treatment effective rate in the treatment group was 90.7% (39/43), significantly higher than the 64.3% (27/42) in the control group (P < 0.01). The Traditional Chinese Medicine (TCM) syndrome scores in the observation group decreased significantly (P <0.01), while in the control group, although there was a reduction in scores, the difference was not statistically significant (P > 0.05). Following treatment, the FIB-4 index decreased in both groups, but the improvement in the treatment group was significantly better than that in the control group (P < 0.05, P < 0.01). The lipid profile improvement in the treatment group was significantly better than that in the control group(P < 0.05). Specifically, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in the treatment group decreased significantly (P <0.01), triglycerides (TG) decreased markedly (P <0.05), and high-density lipoprotein cholesterol (HDL-C) showed slight improvement but the difference was not statistically significant (P >0.05). In the control group, TC decreased significantly (P < 0.05), but the reductions in TG, HDL-C, and LDL-C were not statistically significant (P >0.05). The HbA1c levels in the treatment group decreased significantly (P <0.05), while no significant improvement was observed in the HbA1c levels of the control group (P >0.05). The estimated glomerular filtration rate (eGFR) in the treatment group increased significantly (P < 0.05), while 24-hour urine total protein (24h UTP), serum creatinine (Scr) and uric acid (UA) decreased significantly (P < 0.05). No significant improvement was observed in blood urea nitrogen (BUN) (P > 0.05). In the control group, although there were improvements in 24h UTP, eGFR, Scr, BUN, and UA, the differences were not statistically significant (P > 0.05).

Tongxuan Qishen formula can significantly improve the FIB-4 index, renal function, and metabolism-related clinical indicators in DN patients with spleen-kidney deficiency, blood stasis and water stagnation syndrome. It reduces the accumulation of metabolic products in the human body and plays an important role in reducing the risk of liver fibrosis, improving renal function, and delaying disease progression.

To investigate the clinical efficacy of Jiedu Yizhi Formula for Alzheimer's disease (AD) based on the theory of "marrow deficiency and toxin damage. "

A total of 88 AD patients admitted to Shanghai Pudong Hospital from June 2024 to March 2025 were enrolled and randomly divided into an observation group (conventional treatment + Jiedu Yizhi Formula) and a control group (conventional treatment), with 44 cases in each group. The therapeutic efficacy was compared between the two groups after 12 weeks of treatment. Cognitive function [Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA)], activities of daily living [Activity of Daily Living Scale (ADL), Barthel Index], cerebral microcirculation (vertebrobasilar artery blood flow velocity), oxidative stress indicators [superoxide dismutase (SOD), malondialdehyde (MDA), β-amyloid (Aβ)], and inflammatory indicators [interleukin (IL)-1β, IL-6, tumor necrosis factor-alpha (TNF-α)] were assessed before treatment and after 12 weeks of treatment.

After 12 weeks of treatment, the total effective rate in the observation group was higher than that in the control group (P <0.05). After 12 weeks of treatment, the MMSE, MoCA, Barthel Index scores, cerebral microcirculation indicators (left vertebral artery, right vertebral artery, basilar artery), and SOD levels in the observation group were increased compared with before treatment (P < 0.05) and were higher than those in the control group (P < 0.05). The ADL score, MDA, Aβ, IL-1β, and TNF-α levels in the observation group were decreased compared with before treatment (P < 0.05) and were lower than those in the control group (P < 0.05). There was no significant difference in IL-6 levels between the two groups before treatment and after 12 weeks of treatment (P > 0.05).

Jiedu Yizhi Formula demonstrates good clinical efficacy in treating Alzheimer's disease, significantly improving cognitive function and activities of daily living. The mechanism may be related to improving cerebral microcirculation and reducing oxidative stress and inflammation levels.

To explore the clinical efficacy of Sijun Wendan Formula combined with Febuxostat tablets in the treatment of gouty nephropathy and its impact on patients' renal function.

A total of 148 patients with gout nephropathy admitted to the Department of Nephrology and Rheumatology of Anqing First People's Hospital (from January 2023 to January 2025) were included in this study. The patients were evenly divided into two groups by the random number table method. Patients in the control group (74 cases) were treated with febuxostat tablets. Patients in the observation group (74 cases) were treated with Febuxostat Tablets + Sijun Wendan Formula. During the study, 3 cases dropped out in the control group and 2 cases in the observation group. Eventually, there were 72 cases in the observation group and 71 cases in the control group. Observe the therapeutic effects of the two groups of patients, the TCM syndrome scores before and after treatment (such as frequent nocturia, low back pain, joint swelling and pain, etc.), procalcitonin (PCT), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum uric acid (UA), blood urea nitrogen (BUN), serum creatinine (Scr), glomerular filtration rate (eGFR), and the level of 24-hour urine protein quantification (24h UTP) and adverse reactions.

The curative effect of observation group was higher than that of control group(P < 0.05); After treatment, TCM symptom scores (nocturnal frequent urination, lumbago, joint swelling pain, etc.), PCT, CRP, ESR, UA, BUN, Scr, 24h UTP levels were decreased in both groups (P < 0.05), and eGFR levels were increased(P < 0.05). After treatment, the TCM syndrome scores (nocturnal frequent urination, lumbago, joint swelling pain, etc.), PCT, CRP, ESR, UA, BUN, Scr, 24h UTP levels in observation group were lower than those in control group(P < 0.01), and eGFR levels were higher than those in control group(P < 0.05); The incidence of adverse reactions in observation group was lower than that in control group (P <0.01).

The combination of Sijun Wendan Formula and Febuxostat tablets has a good clinical effect in the treatment of gouty nephropathy, and can effectively improve patients' symptoms and renal function. The treatment is safe and reliable.

To explore the clinical efficacy of Huatan Xiaoyu Formula in the treatment of gastric precancerous lesions and its effect on pepsin and circulating tumor cells (CTC).

A total of 110 gastric precancerous lesions patients with syndrome of phlegm-and-blood stasis obstructing collaterals who received treatment in the First Affiliated Hospital of Nanjing Medical University from January 2022 to January 2024 were randomly divided into two groups: the conventional group (n = 55) and the Huatan Xiaoyu Formula group (n = 55). Compare the efficacy of two groups of patients, including symptom scores, laboratory indicators (including pepsinogen I (PGⅠ), pepsinogen Ⅱ (PGⅡ), malondialdehyde (MDA), superoxide dismutase (SOD), epidermal growth factor (EGF), tumor necrosis factor a (TNF-α)), and positive detection rate of CTC before and after treatment. The adverse reactions of the two groups were observed.

The total effective rate of the Huatan Xiaoyu Formula group was higher than that of the conventional group (P <0.05). After treatment, both groups showed a decrease in epigastric fullness, epigastric pain, loose stools, thirst and total score, and the Huatan Xiaoyu Formula group was lower than the conventional group (P <0.05). After treatment, the score of WHOQOL-BREF in both groups was increased, and Huatan Xiaoyu Formula group was higher than that in conventional group (P <0.05). After treatment, the levels of PGⅠ and PGⅠ/Ⅱ in both groups increased, and the Huatan Xiaoyu Formula group was higher than the conventional group (P <0.05); The levels of PGII in both groups decreased, and the group of Huatan Xiaoyu Formula was lower than the conventional group (P <0.05). After treatment, the levels of MDA, TNF-α and EGF in both groups decreased, and the Huatan Xiaoyu Formula group was lower than the conventional group (P <0.05); The levels of SOD in both groups increased, and the Huatan Xiaoyu Formula group was higher than the conventional group (P < 0.05). The positive rate of CTC in the Huatan Xiaoyu Formula group was lower than that in the conventional group (P < 0.05). There was no significant difference in adverse reactions between the two groups (P >0.05).

Huatan Xiaoyu Formula can effectively treat gastric precancerous lesions, improve symptom scores, gastrointestinal hormone levels, reduce levels of oxidative stress related factors, body inflammation, and the positive rate of CTC.

To analyze the effect of Tianma Gegen decoction on ischemic stroke (Wind-Phlegm-Stasis Blocking Syndrome).

The clinical data of 105 patients with ischemic stroke (Wind-Phlegm-Stasis blocking syndrome) admitted to Rugao Hospital of Traditional Chinese Medicine during January 2021 to December 2023 were retrospectively analyzed. According to different treatment methods, they were divided into control group (n = 55, conventional treatment) and observation group (n = 50, conventional treatment + modified Tianma Gegen decoction). After 2 weeks of continuous treatment, the clinical efficacy, adverse reactions, and TCM symptom scores, degree of neurological impairment [National Institutes of Health Stroke Scale (NIHSS) score], serum indexes [neuron-specific enolase (NSE), matrix metalloproteinase (MMP)-9, intercellular adhesion molecule (ICAM)-1, monocyte chemoattractant protein(MCP)-1] levels before and after treatment were evaluated.

The total effective rate of observation group was 98.00%(49/50), which was higher than that of control group 85.45%(47/55) (P < 0.05). Compared with before treatment, TCM syndrome score, NIHSS score and serum levels of NSE, MMP-9, ICAM-1 and MCP-1 in both groups were decreased after treatment(P < 0.01), and the observation group was lower than the control group(P < 0.01). The total incidence of adverse reactions in observation group and control group was 8.00%(4/50) and 5.45%(3/55), respectively, with no statistical significance(P > 0.05).

The modified Tianma Gegen decoction in the treatment of ischemic stroke (Wind-Phlegm-Stasis Blocking Syndrome) can improve the therapeutic effect, alleviate symptoms, reduce the levels of serum NSE, MMP-9, ICAM-1 and MCP-1, which is conducive to the improvement of neurological impairment, and will not increase the occurrence of adverse reactions.

To explore the clinical effect of combination of Dachaihu Decoction and amlodipine besylate in treating hypertension with liver-fire hyperactivity syndrome.

A total of 148 hypertensive patients with liver-fire hyperactivity syndrome admitted to Pingyi County Traditional Chinese Medicine Hospital between January 2022 and January 2025 were divided into control group (n = 74, amlodipine besylate) and combined group (n = 74, Dachaihu Decoction combined with amlodipine besylate) according to the random number table method. The clinical efficacy, TCM symptoms scores and 24 h ambulatory blood pressure were compared between both groups, and the safety and quality of life in the two groups were evaluated.

Compared with the control group, the clinical efficacy in the combined group was enhanced after treatment (P < 0. 05) while the scores of TCM syndromes were reduced (P <0.05). The 24 h average systolic, 24 h average diastolic blood pressures, daytime average systolic blood pressure, daytime average diastolic blood pressure, nighttime average systolic blood pressure and nighttime average diastolic blood pressure in the combined group after treatment were decreased compared with those in the control group (P < 0.05). The scores of various dimensions of quality of life brief scale were increased in the combined group after treatment (P <0.05). No significant difference was exhibited in the occurrence of adverse reactions between groups (P > 0.05).

Dachaihu Decoction combined with amlodipine besylate has significant efficacy in the treatment of hypertensive patients with liver-fire hyperactivity syndrome, and it can effectively reduce blood pressure, improve symptoms, and enhance the quality of life, with guaranteed safety.

To investigate the efficacy of Buyang Huanwu Decoction combined with "Shao's Five-Needle Technique" in treating unstable angina pectoris (UA) of coronary heart disease.

Using a random number table method, 120 patients with UA of coronary heart disease admitted to Baoji Hospital of Traditional Chinese Medicine from January 2023 to July 2024 were divided into a decoction group, an acupuncture group, and a combination group, with 40 cases in each group. All three groups received conventional treatment. Additionally, the decoction group was treated with Buyang Huanwu Decoction, the acupuncture group was treated with "Shao's Five-Needle Technique," and the combination group was treated with Buyang Huanwu Decoction combined with "Shao's Five-Needle Technique." One treatment course consisted of 10 days, and all groups were treated for 2 courses. The clinical efficacy of angina pectoris, electrocardiogram efficacy, and adverse reactions were compared among the three groups. TCM syndrome scores, clinical symptoms, cardiac function, blood lipids, and serum inflammatory indicators were recorded before and after treatment in each group.

The overall comparison of the total clinical effective rates and total electrocardiogram effective rates among the three groups showed statistically significant differences (P <0.05). After treatment, the total TCM syndrome scores, clinical symptom-related indicators of angina pectoris, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and serum levels of interleukin (IL)-6, IL-1β, high-sensitivity C-reactive protein (hs-CRP), and tumor necrosis factor-α(TNF-α) decreased in all three groups compared with those before treatment (P < 0.05). The combination group had lower total TCM syndrome scores, clinical symptoms of angina pectoris, TC, LDL-C, and serum inflammatory-related indicators than the decoction group and acupuncture group (P <0.05). After treatment, the cardiac ejection fraction (EF), stroke volume (SV), and high-density lipoprotein cholesterol (HDL-C) increased in all three groups compared with those before treatment (P < 0.05). The combination group had higher EF and SV than the decoction group and acupuncture group (P <0.05). There were no statistically significant differences in any indicators between the decoction group and the acupuncture group (P > 0.05). The comparison of the total incidence of adverse reactions among the three groups showed no statistically significant difference (P > 0.05).

Buyang Huanwu Decoction combined with "Shao's Five-Needle Technique" is safe and effective in treating UA of coronary heart disease. It significantly improves angina symptoms and cardiac function, with notable lipid-regulating and anti-inflammatory effects.